BridgeMD
New treatment option for Macular Holes
Official title Full-Thickness Macular Hole Surgery: A Comparison of Ten Techniques
ClinicalTrials.gov ID: NCT07606404
What this study is testing
What is Autologous Platelet-Rich Plasma (PRP)?
Autologous Platelet-Rich Plasma (PRP) is an investigational medicine, being studied as a potential treatment for macular holes.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study compares ten modern vitreoretinal surgical techniques for full-thickness macular hole repair. Participants will be randomly assigned to one of the surgical approaches during pars plana vitrectomy, using stratified randomization based on macular hole size to ensure balanced groups.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults aged ≥18 years.
- Full-thickness macular hole (FTMH) eligible for pars plana vitrectomy (PPV).
- Symptom duration ≤12 months.
- Clear ocular media sufficient for high-quality OCT imaging.
- No prior pars plana vitrectomy in the study eye.
You likely can't join if
- A. Etiology-Related / Secondary Macular Holes:
- Traumatic macular hole.
- High myopia with posterior staphyloma (axial length \>28 mm and/or spherical equivalent ≤-8.0 D).
- Diabetic tractional retinal detachment (TRD) or significant tractional maculopathy.
- Retinal vascular occlusion-related macular hole.
- Uveitis-related macular hole.
See the full eligibility criteria
- Adults aged ≥18 years.
- Full-thickness macular hole (FTMH) eligible for pars plana vitrectomy (PPV).
- Symptom duration ≤12 months.
- Clear ocular media sufficient for high-quality OCT imaging.
- No prior pars plana vitrectomy in the study eye.
- No severe foveal atrophy on OCT.
- Able and willing to comply with postoperative positioning and follow-up visits.
- Written informed consent provided.
- A. Etiology-Related / Secondary Macular Holes:
- Traumatic macular hole.
- High myopia with posterior staphyloma (axial length \>28 mm and/or spherical equivalent ≤-8.0 D).
- Diabetic tractional retinal detachment (TRD) or significant tractional maculopathy.
- Retinal vascular occlusion-related macular hole.
- Uveitis-related macular hole.
- Advanced age-related macular degeneration (AMD) with foveal atrophy.
- B. Prior Interventions:
- Any prior pars plana vitrectomy in the study eye.
- C. Ocular Conditions That May Affect Outcomes or Safety:
- Active or recent ocular infection or inflammation (e.g., uveitis, endophthalmitis, keratitis).
- Uncontrolled glaucoma (intraocular pressure \>28 mmHg despite treatment).
- Media opacity precluding adequate OCT (e.g., dense cataract or corneal opacity).
- Geographic atrophy involving the fovea.
The study team makes the final eligibility decision.
Where it's taking place
- Almaty, Almaty, Kazakhstan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Almaty, Almaty, Kazakhstan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.